CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Takeda Pharmaceutical Company Limited - 4502 CFD

    4790.49
    0.76%
    32.92
    Low: 4772.53
    High: 4809.74
    Market Trading Hours* (UTC) Opens on Wednesday at 00:00

    Mon - Fri: 00:00 - 02:30 03:30 - 06:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 32.92
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.010986 %
    Charges from full value of position ($-2.09)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.010986%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.011237 %
    Charges from full value of position ($-2.14)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.011237%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency JPY
    Margin 5%
    Stock exchange Japan
    Commission on trade 0%

    *Information provided by Capital.com

    Takeda Pharmaceutical Co Ltd ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 4754.58
    Open* 4772.53
    1-Year Change* 26.2%
    Day's Range* 4772.53 - 4809.74
    52 wk Range 3,663.00-4,645.00
    Average Volume (10 days) 3.51M
    Average Volume (3 months) 77.55M
    Market Cap 7,161.70B
    P/E Ratio 23.56
    Shares Outstanding 1.55B
    Revenue 4,113.63B
    EPS 192.12
    Dividend (Yield %) 3.97702
    Beta 1.00
    Next Earnings Date Oct 26, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 26, 2023 4802.56 15.07 0.31% 4787.49 4810.84 4759.56
    Sep 25, 2023 4754.58 34.91 0.74% 4719.67 4771.64 4719.67
    Sep 22, 2023 4693.74 -18.95 -0.40% 4712.69 4736.03 4682.77
    Sep 21, 2023 4739.72 -41.79 -0.87% 4781.51 4788.90 4725.66
    Sep 20, 2023 4800.46 -12.57 -0.26% 4813.03 4823.50 4786.49
    Sep 19, 2023 4812.43 22.94 0.48% 4789.49 4835.57 4784.39
    Sep 15, 2023 4845.34 47.87 1.00% 4797.47 4859.42 4776.52
    Sep 14, 2023 4788.49 78.79 1.67% 4709.70 4809.55 4678.16
    Sep 13, 2023 4698.72 22.93 0.49% 4675.79 4708.90 4642.87
    Sep 12, 2023 4649.95 101.83 2.24% 4548.12 4685.17 4542.14
    Sep 11, 2023 4529.17 25.53 0.57% 4503.64 4536.56 4484.29
    Sep 8, 2023 4499.35 -34.81 -0.77% 4534.16 4542.73 4497.26
    Sep 7, 2023 4516.31 11.07 0.25% 4505.24 4531.47 4497.36
    Sep 6, 2023 4510.22 1.99 0.04% 4508.23 4531.57 4502.24
    Sep 5, 2023 4530.17 18.95 0.42% 4511.22 4534.26 4505.24
    Sep 4, 2023 4520.19 23.83 0.53% 4496.36 4523.69 4473.32
    Sep 1, 2023 4495.26 11.97 0.27% 4483.29 4511.32 4476.31
    Aug 31, 2023 4489.27 20.94 0.47% 4468.33 4508.53 4462.34
    Aug 30, 2023 4474.31 19.94 0.45% 4454.37 4489.38 4443.39
    Aug 29, 2023 4457.46 -6.88 -0.15% 4464.34 4478.41 4452.37

    Takeda Pharmaceutical Company Limited Events

    Time (UTC) Country Event
    Thursday, September 28, 2023

    Time (UTC)

    12:00

    Country

    JP

    Event

    Takeda Pharmaceutical Co Ltd
    Takeda Pharmaceutical Co Ltd

    Forecast

    -

    Previous

    -
    Thursday, October 26, 2023

    Time (UTC)

    06:00

    Country

    JP

    Event

    Q2 2024 Takeda Pharmaceutical Co Ltd Earnings Release
    Q2 2024 Takeda Pharmaceutical Co Ltd Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, January 31, 2024

    Time (UTC)

    06:00

    Country

    JP

    Event

    Q3 2024 Takeda Pharmaceutical Co Ltd Earnings Release
    Q3 2024 Takeda Pharmaceutical Co Ltd Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total revenue 4027480 3569010 3197810 3291190 2097220
    Revenue 4027480 3569010 3197810 3291190 2097220
    Cost of Revenue, Total 1244070 1106850 994308 1089760 651729
    Gross Profit 2783410 2462160 2203500 2201420 1445500
    Total Operating Expense 3494180 3123810 2596860 3193730 1874650
    Selling/General/Admin. Expenses, Total 997309 886361 875663 964737 717599
    Research & Development 633325 526087 455833 492381 368298
    Depreciation / Amortization 542443 472915 421864 455420 178617
    Unusual Expense (Income) 21593 100290 -265230 189043 -41201
    Other Operating Expenses, Total 55443 31309 114422 2384 -2507
    Operating Income 533293 445198 600952 97459 222577
    Interest Income (Expense), Net Non-Operating -158203 -142628 -234717 -158213 -94965
    Other, Net 1
    Net Income Before Taxes 375090 302571 366235 -60754 127612
    Net Income After Taxes 317038 230166 376171 44290 135080
    Minority Interest -21 -107 -166 -49 112
    Net Income Before Extra. Items 317017 230059 376005 44241 135192
    Net Income 317017 230059 376005 44241 135192
    Income Available to Common Excl. Extra. Items 317017 230059 376005 44241 135192
    Income Available to Common Incl. Extra. Items 317017 230059 376005 44241 135192
    Diluted Net Income 317017 230059 376005 44241 135192
    Diluted Weighted Average Shares 1569.87 1577.17 1573.54 1566.2 966.897
    Diluted EPS Excluding Extraordinary Items 201.938 145.868 238.955 28.2473 139.82
    Dividends per Share - Common Stock Primary Issue 180 180 180 180 180
    Diluted Normalized EPS 213.564 194.24 129.394 106.703 112.123
    Interest Expense (Income) - Net Operating 2112
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1058620 956156 1096550 1002310 972465
    Revenue 1058620 956156 1096550 1002310 972465
    Cost of Revenue, Total 321114 309772 335973 305445 292882
    Gross Profit 737504 646384 760578 696862 679583
    Total Operating Expense 890047 867594 949561 897869 821950
    Selling/General/Admin. Expenses, Total 248113 254796 262299 248734 231480
    Research & Development 162741 160944 174629 154145 143607
    Depreciation / Amortization 129423 133224 135576 142366 131277
    Unusual Expense (Income) 11243 14898
    Other Operating Expenses, Total 28656 -2385 26186 47179 22704
    Operating Income 168571 88562 146990 104438 150515
    Interest Income (Expense), Net Non-Operating -33538 -40647 -39837 -39890 4959
    Net Income Before Taxes 135033 47915 107153 64549 155473
    Net Income After Taxes 89406 31136 119149 61732 105021
    Minority Interest -11 -2 -22 10 -7
    Net Income Before Extra. Items 89395 31134 119127 61742 105014
    Net Income 89395 31134 119127 61742 105014
    Income Available to Common Excl. Extra. Items 89395 31134 119127 61742 105014
    Income Available to Common Incl. Extra. Items 89395 31134 119127 61742 105014
    Diluted Net Income 89395 31134 119127 61742 105014
    Diluted Weighted Average Shares 1565.04 1583.78 1570.42 1563.73 1545.71
    Diluted EPS Excluding Extraordinary Items 57.1199 19.658 75.857 39.4837 67.9392
    Dividends per Share - Common Stock Primary Issue 0 90 0 90 0
    Diluted Normalized EPS 57.1199 24.2709 82.0233 39.4837 67.9392
    Total Adjustments to Net Income 0
    Other, Net 1 -1
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total Current Assets 2397960 2593640 2712890 2469430 2993040
    Cash and Short Term Investments 553704 875000 1002820 653436 725819
    Cash & Equivalents 533530 389058 335027 188640 462890
    Short Term Investments 20174 485942 667793 464796 262929
    Total Receivables, Net 681693 724377 812714 784921 749119
    Accounts Receivable - Trade, Net 649429 617517 707487 670708 657681
    Total Inventory 986457 853167 753881 759599 919670
    Other Current Assets, Total 176102 141098 143478 271476 598429
    Total Assets 13957800 13178000 12912300 12821100 13792800
    Property/Plant/Equipment, Total - Net 1691230 1582800 1453920 1386370 1331930
    Property/Plant/Equipment, Total - Gross 2453010 2191740 2084120 1971520
    Accumulated Depreciation, Total -870208 -737818 -697754 -639591
    Goodwill, Net 4790720 4407750 4033920 4012530 4240250
    Intangibles, Net 4269660 3818540 3909110 4171360 4751170
    Long Term Investments 378857 330133 348350 369455 299922
    Other Long Term Assets, Total 429328 445150 454110 411948 176463
    Total Current Liabilities 2481940 2145730 1773180 2175900 2553050
    Accounts Payable 649233 295933 232105 211627 212348
    Notes Payable/Short Term Debt 285 69 5014 500002
    Current Port. of LT Debt/Capital Leases 339600 203708 22084 581803 484944
    Other Current Liabilities, Total 1493110 1645800 1518920 1377450 1355760
    Total Liabilities 7603630 7495000 7739260 8097610 8610790
    Total Long Term Debt 4042740 4141420 4613220 4506490 4766000
    Long Term Debt 4042740 4141420 4613220 4506490 4766000
    Deferred Income Tax 295178 473145 576542 765079 783356
    Minority Interest 549 504 4140 4003 4006
    Other Liabilities, Total 783219 734202 772180 646144 504372
    Total Equity 6354120 5683020 5173040 4723480 5181980
    Common Stock 1676340 1676260 1668140 1668120 1643580
    Additional Paid-In Capital 1728830 1708870 1688420 1680290 1650230
    Retained Earnings (Accumulated Deficit) 1541150 1479720 1509910 1369970 1595430
    Treasury Stock - Common -100317 -116007 -59552 -87463 -57142
    Unrealized Gain (Loss) 12470 22068 41983 22891 46380
    Other Equity, Total 1495650 912106 324131 69673 303499
    Total Liabilities & Shareholders’ Equity 13957800 13178000 12912300 12821100 13792800
    Total Common Shares Outstanding 1554.53 1550.36 1563.36 1557.77 1554.78
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 2397960 2595950 2745620 2549520 2593640
    Cash and Short Term Investments 553704 726608 830069 664534 875000
    Cash & Equivalents 533530 685141 798137 645991 849695
    Short Term Investments 20174 41467 31932 18543 25305
    Total Receivables, Net 681693 779872 800536 794092 724377
    Accounts Receivable - Trade, Net 649429 707318 759894 762126 696644
    Total Inventory 986457 927286 953450 927511 853167
    Other Current Assets, Total 176102 162180 161561 163378 141098
    Total Assets 13957800 13504700 14588800 14065400 13178000
    Property/Plant/Equipment, Total - Net 1691230 1656420 1760330 1705370 1582800
    Goodwill, Net 4790720 4690950 4994630 4813610 4407750
    Intangibles, Net 4269660 3765760 4187060 4145090 3818540
    Long Term Investments 378857 369469 425766 381607 330133
    Other Long Term Assets, Total 429328 426168 475451 470237 445150
    Total Current Liabilities 2481940 2236810 2391720 2166940 2145730
    Accounts Payable 649233 381109 388616 424358 516297
    Notes Payable/Short Term Debt 0 0 0 285
    Current Port. of LT Debt/Capital Leases 339600 372019 568228 281897 203708
    Other Current Liabilities, Total 1493110 1483680 1434880 1460690 1425440
    Total Liabilities 7603630 7328730 7875920 7748590 7495000
    Total Long Term Debt 4042740 3914880 4168420 4320360 4141420
    Long Term Debt 4042740 3914880 4168420 4320360 4141420
    Deferred Income Tax 295178 413833 493229 483372 473145
    Minority Interest 549 520 560 551 504
    Other Liabilities, Total 783219 762681 821992 777372 734202
    Total Equity 6354120 6175980 6712930 6316830 5683020
    Common Stock 1676340 1676330 1676330 1676280 1676260
    Additional Paid-In Capital 1728830 1712040 1695540 1707340 1708870
    Retained Earnings (Accumulated Deficit) 1541150 1507720 1530200 1459760 1479720
    Treasury Stock - Common -100317 -100314 -100313 -129184 -116007
    Unrealized Gain (Loss) 13341 16819 17163 22068
    Other Equity, Total 1508120 1366860 1894350 1585480 912106
    Total Liabilities & Shareholders’ Equity 13957800 13504700 14588800 14065400 13178000
    Total Common Shares Outstanding 1554.53 1554.52 1554.52 1546.1 1550.36
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Net income/Starting Line 317038 230166 376171 44290 109014
    Cash From Operating Activities 977156 1123100 1010930 670381 328301
    Cash From Operating Activities 664400 583151 559671 583649 272446
    Non-Cash Items 327626 252109 12308 172928 39061
    Cash Taxes Paid 185966 140423 201687 226768 44909
    Cash Interest Paid 108555 108207 107350 127211 34914
    Changes in Working Capital -331908 57679 62781 -130486 -92220
    Cash From Investing Activities -607102 -198125 393530 292119 -2835700
    Capital Expenditures -633689 -186037 -236468 -217710 -134114
    Other Investing Cash Flow Items, Total 26587 -12088 629998 509829 -2701580
    Cash From Financing Activities -709148 -1070260 -1088350 -1005210 2946240
    Financing Cash Flow Items -117732 -108592 -142352 -132804 -71143
    Total Cash Dividends Paid -279416 -283665 -283357 -282582 -142952
    Issuance (Retirement) of Stock, Net -26929 -77531 -2141 -3737 -1172
    Issuance (Retirement) of Debt, Net -285071 -600477 -660504 -586090 3161500
    Foreign Exchange Effects 22929 28758 12501 -21766 -31269
    Net Change in Cash -316165 -116527 328608 -64479 407571
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 317038 285903 166753 105021 230166
    Cash From Operating Activities 977156 683463 305234 84241 1123100
    Cash From Operating Activities 664400 502990 326110 158283 583151
    Non-Cash Items 327626 218641 140497 51740 252109
    Cash Taxes Paid 185966 165066 109217 20855 140423
    Cash Interest Paid 108555 86563 52719 22770 108207
    Changes in Working Capital -331908 -324071 -328126 -230803 57679
    Cash From Investing Activities -607102 -168610 -121920 -94714 -198125
    Capital Expenditures -633689 -189609 -138985 -98376 -186037
    Other Investing Cash Flow Items, Total 26587 20999 17065 3662 -12088
    Cash From Financing Activities -709148 -702548 -267593 -215717 -1070260
    Financing Cash Flow Items -117732 -92527 -52761 -22786 -108592
    Total Cash Dividends Paid -279416 -268997 -140007 -128873 -283665
    Issuance (Retirement) of Stock, Net -26929 -26929 -26929 -26929 -77531
    Issuance (Retirement) of Debt, Net -285071 -314095 -47896 -37129 -600477
    Foreign Exchange Effects 22929 23141 32720 22485 28758
    Net Change in Cash -316165 -164554 -51559 -203705 -116527

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Takeda Pharmaceutical Company Limited Company profile

    About Takeda Pharmaceutical Co Ltd

    Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

    Financial summary

    BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.

    Equity composition

    FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.

    Industry: Pharmaceuticals (NEC)

    4階
    日本橋本町二丁目1番1号
    CHUO-KU
    TOKYO-TO 103-8668
    JP

    Income Statement

    • Annual
    • Quarterly

    News

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023

    People also watch

    Oil - Crude

    90.08 Price
    +0.720% 1D Chg, %
    Long position overnight fee 0.0445%
    Short position overnight fee -0.0664%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    BTC/USD

    26,202.40 Price
    -0.420% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.51 Price
    +0.480% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,554.20 Price
    -1.450% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading